[Barriers for Implementation of PGx Testing in Psychiatric Hospitals in Germany: Results of the FACT-PGx Study]. / Barrieren bei der Implementierung pharmakogenetischer Testungen in der Psychiatrie in Deutschland Ergebnisse aus der FACT-PGx Studie.
Fortschr Neurol Psychiatr
; 2023 May 02.
Article
em De
| MEDLINE
| ID: mdl-37130546
ABSTRACT
OBJECTIVE:
The FACT-PGx study was conducted to analyze barriers to implementation of pharmacogenetic testing in psychiatric hospitals in Germany and to propose solutions for its faster and easier implementation in all hospitals.METHODS:
104 patients (50% female) were genotyped and participated in the study. 67 completed a survey. To analyze the correlation between continuous data (age) of the survey, the wilcoxon rank test and for categorial data (education level, history of treatment and episodes), t-test was used.RESULTS:
No patient declined to be genotyped. 99% believed that genotyping could help to shorten their hospital stay. Patients >40 years of age and with higher educational levels were willing to pay for the PGx (p=0.009). On average, patients were willing to pay 117.42 +/-140.49 and to wait 15.83+/- 8.92 days for the results. Processes differed significantly between routine laboratory screening and PGx testing which could be a barrier for implementation.CONCLUSION:
Patients are not barriers to but enablers of an implementation of PGx. New process flows can be barriers, but can be overcome by optimization.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
De
Revista:
Fortschr Neurol Psychiatr
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Alemanha